Experience

Nasus Pharma

• Israel
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Board Member

  • Jan 2019 - Present

  Based on its unique microsphere technology Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations. Taffix™ is a Nasal powder and personal inhaler that blocks viruses from entering the nasal cells. It creates a unique thin gel over the nasal mucosa which lasts 4-5 hours and significantly shields the cells from inhaled viruses through both mechanical and chemical protection. While the COVID-19 pandemic brought the economy to a standstill world-wide, protection of the civil population is critical to overcoming the infection. The next phase, “Back to Normality,” is the primary objective of governments and public health focused organizations. Preventing another wave while returning gradually to normality will necessitate strict preventive measures. Intranasal powder drug delivery has an inherent advantage over solutions due to the higher dispersion of the drug particles in the nasal cavity. Nasus powder technology was tested in clinical studies and proved to be superior to a similar solution-based drug: 7 times higher absorption in the first 4 minutes and 4 times higher absorption in the first 10 minutes. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety. Intranasal administration bypasses the massive liver metabolism and can deliver drugs directly to the brain (nose to brain). It enables the rescue of patients by caregivers and non-professional personnel and has the potential to save lives in life-threatening situations where prompt treatment is critical. Show less



Hershman Holdings LLC

• Founder, Principal and Owner

  • 2004 - Present

  As an Angel Investor, Dr. Hershman is the Founder and Principal Owner of Hershman Holdings. Dr. Hershman has participated as an investor in CommunityLeader Inc (Silicon Valley), CLiHealth (Silicon Valley), HealthEffect LLC (New York City), Signet Healthcare Partners (New York City), OurCrowd (Israel), Solubest Ltd (Israel), Optivasive Ltd (Israel), and Targia Ltd (Israel). As an Angel Investor, Dr. Hershman is the Founder and Principal Owner of Hershman Holdings. Dr. Hershman has participated as an investor in CommunityLeader Inc (Silicon Valley), CLiHealth (Silicon Valley), HealthEffect LLC (New York City), Signet Healthcare Partners (New York City), OurCrowd (Israel), Solubest Ltd (Israel), Optivasive Ltd (Israel), and Targia Ltd (Israel).



HealthEffect

• United States
• Hospitals and Health Care

• Co-founder & CEO

  • Aug 2015 - Present

  HealthEffect is a Healthcare-specific online marketplace where a global community collaborates to bring medical innovations to market quicker, and improve the health of the world. HealthEffect seeks to disrupt the current process of Health Innovation by leveraging emerging technologies in the domains of Talent Marketplaces, Crowdsolving, and Equity Crowdfunding, rolling them all into one tech platform. HealthEffect aims to do well by providing outsized investor returns, but is also on a mission to do good, by making a powerful impact on the way Health Innovation affects the overall condition of human life. Show less



InvestEffect

• Germany
• IT Services and IT Consulting
• 1 - 100 Employee

• Co-Founder & CEO

  • Jan 2017 - Present

  InvestEffect is a tech-enabled biotech fund and accelerator that sources and accelerates companies via expert vetting and online voting, and applying seed capital via our own PE fund. On the InvestEffect platform, early-stage companies apply to be vetted by a pool of talented experts. Having subscribed to channels of interest, experts are notified of new applicants and may evaluate them in exchange for cash, equity or a board position. If companies are voted into the accelerator, InvestEffect's own PE fund kicks in the initial capital, restructures the company, and begins sourcing operational resources via our platform technology. Ultimately, additional capital is raised and the company proceeds toward an exit. InvestEffect's technology streamlines the accelerator model and propels companies toward success. This online/virtual "Y-Combinator" is fueled by an engaging "Shark Tank" style expert voting process, fostering engagement for all stakeholders. Our technology provides for the sourcing and engaging of human capital (i.e. staffing), intellectual capital (i.e. advice online), and financial capital, with the sale and settlement of private securities occurring online in a legally compliant environment. Show less



CLiHealth

• United Kingdom
• IT Services and IT Consulting

• CEO

  • 2015 - Present

  We build and support securities-based crowdfunding portals for Health Innovators. Our software is white-labeled and integrates seamlessly with any website. It's user friendly with an incredible number of features, and growing all the time. We build and support securities-based crowdfunding portals for Health Innovators. Our software is white-labeled and integrates seamlessly with any website. It's user friendly with an incredible number of features, and growing all the time.



CommunityLeader

• United States
• Software Development
• 1 - 100 Employee

• Director

  • 2015 - Present

  CommunityLeader is the leader in the development and support of online investment platforms. With over 150 years of industry expertise, our leadership team has an unprecedented understanding of the regulatory environment, due diligence process, transactional technology and investor marketing which directly impacts the success of your platform. Since the passage of the rules allowing for the general solicitation of private securities, no one has designed, built or supported more investment platforms than CommunityLeader. Show less


Targia Ltd
• United Kingdom
• Restaurants
• Director

  • 2015 - Present


NYU Langone Long Island Cardiac Care

• United States
• Hospitals and Health Care
• 1 - 100 Employee

• Medical Director

  • Jan 2012 - Present

  I specialize in cardiac catheterization, heart failure, nuclear medicine imaging procedure, heart attack, coronary heart disease, carotid artery disease, heart ultrasound, congestive heart failure (CHF), arteriosclerosis, lipid metabolism, heart muscle disease, chest pain, pacemaker care, high blood pressure disorder, cardiovascular imaging, abnormal heart rhythms, vascular ultrasound I specialize in cardiac catheterization, heart failure, nuclear medicine imaging procedure, heart attack, coronary heart disease, carotid artery disease, heart ultrasound, congestive heart failure (CHF), arteriosclerosis, lipid metabolism, heart muscle disease, chest pain, pacemaker care, high blood pressure disorder, cardiovascular imaging, abnormal heart rhythms, vascular ultrasound


Optivasive Ltd
• Director

  • 2009 - Present


SoluBest Ltd.

• Israel
• Nanotechnology Research
• 1 - 100 Employee

• Chairman of the Board

  • 2004 - Present

  SoluBest was founded in 2001 to develop an easy-to-integrate technological platform for solving one of the most pressing issues facing the Pharma industry: the problem of drug insolubility. Privately owned and funded, SoluBest has recently concluded its 4th round of financing. SoluBest is pursuing a Two-Pronged Business Model: On one hand, Solubest establishes multiple customized services through leverage on its expertise in the development of challengeable formulations. This ongoing model results in short term income and long term royalties based income, and/or supply opportunities in Pharma and non-Pharma applications (Nutraceuticals, Agro, and so forth). On the other hand Solubest spins off the matured, in vivo and/or clinically proven products into new ventures focused on product approvals and commercialization. Such a model adds value through equity-based joint ventures, and/or licensing-out agreements based on down- and milestones-payments. Several JVs are currently being formed. Show less



Signet Healthcare Partners

• United States
• Financial Services
• 1 - 100 Employee

• Limited Partner

  • 2002 - Present

  Signet Healthcare Partners (“Signet”) was founded in 1998 to focus on investments in the healthcare sector. Since inception, Signet has raised four funds, with aggregate capital commitments in excess of $400 million, and has invested in more than 45 companies. These investments have generated positive returns for our investors through capital market transactions and M&A exits. Signet is currently making new investments out of its fourth fund (“Fund IV’). The Fund IV team is comprised of three senior investment professionals and a network of venture partners and operating advisors. Throughout our history, we have remained focused on growth-stage healthcare investing. Our team of investment professionals and network of advisors have decades of experience investing in and building successful businesses across capital market cycles. It is our goal to be domain experts and strategic partners to our portfolio companies and their management teams. We maintain a disciplined yet flexible investment approach and understand the steps needed to develop growth-stage companies into leading businesses in a capital efficient manner. We have a concentrated portfolio which enables us to play an active role in building value by working closely with our companies. Show less


Long Island Cardiac Care
• United States
• Higher Education
• Owner

  • 2000 - 2012


Saint Francis Hospital

• United States
• Hospitals and Health Care
• 1 - 100 Employee

• Cardiology and Interventional Cardiology

  • 1989 - 2012

• President, Integrated Cardiovascular Therapeutics

  • 1993 - 2000


Mount Sinai Hospital Interventional Cardiology
• Fellowship and Research in Laser Angioplasty

  • 1987 - 1989